RxDoctor Payments Data

Janine Brink

Family · Geneva, NYNPI 1356510655

Payments from drug & device makers

$487in general payments, 2019–2025

Across 18 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$118
  • AbbVie$96
  • Lundbeck LLC$86
  • Alkermes, Inc.$57
  • Orexo US, Inc.$35
  • Indivior Inc.$32
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$487 in reported general payments places this provider in the 55th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$8,184
Medicare patients
74
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$79,116
TrulicityDulaglutide46$50,623
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$33,496
OzempicSemaglutide18$16,646
MounjaroTirzepatide12$13,107
Xtampza ErOxycodone Myristate12$10,815
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl71$10,781
EliquisApixaban11$10,350
RybelsusSemaglutide11$10,150
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$9,941
Lisdexamfetamine Dimesylate33$6,579
Varenicline Tartrate22$6,442
LinzessLinaclotide11$5,893
VyvanseLisdexamfetamine Dimesylate17$5,317
SymbicortBudesonide/Formoterol Fumarate21$4,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$32$9,94114 claims
AbbVieLinzess$96$5,89311 claims
Orexo US, Inc.Zubsolv$35$2,69411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,883 family providers in New York.

Other family in Geneva

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →